Assessment of Interactions Between IV Methamphetamine and Aripiprazole
Data Collection
Mental Disorders+1
+ Substance-Related Disorders
+ Amphetamine-Related Disorders
Treatment Study
Summary
Study start date: June 1, 2004
Actual date on which the first participant was enrolled.This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.17 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 45 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking. * Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures. Exclusion Criteria: * Please contact the site for more information.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 2 locations
New York University, School of Medicine
New York, United States